skip to the content

Clinical Trials

Colon and Rectal Cancer Study

CALGB 80405:  A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Parients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

Protocol ID

06.06.001T

Protocol Description

This study is being done to find out the effects (good and bad) of different regimens of chemotherapy. The purpose of this study is to determine whether one of the following two combinations: cetuximab plus chemotherapy, or cetuximab plus bevacizumab plus chemotherapy, is better than than the combination of bevacizumab with chemotherapy in patients who do not have K-ras mutations in their tumor tissues.

Eligibility Criteria

Patients with colon or rectal cancer

Primary Investigator(s)

  • Bhoomi Mehrotra, MD

Contact Information

Dale Janson, RPA-C
(718) 470-4408
djanson@lij.edu

Last Update

March 26, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Cancer:
top
top